HC Wainwright reaffirmed their buy rating on shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) in a research note released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock. HC Wainwright also issued estimates for Acumen Pharmaceuticals’ FY2024 earnings at ($1.01) EPS.
Separately, Citigroup raised shares of Acumen Pharmaceuticals to a strong-buy rating in a research report on Friday, July 26th.
Acumen Pharmaceuticals Stock Performance
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.06). During the same period last year, the firm posted ($0.28) earnings per share. Sell-side analysts expect that Acumen Pharmaceuticals will post -1.13 EPS for the current year.
Hedge Funds Weigh In On Acumen Pharmaceuticals
Several institutional investors and hedge funds have recently added to or reduced their stakes in ABOS. Gladius Capital Management LP bought a new position in shares of Acumen Pharmaceuticals in the 2nd quarter worth about $26,000. SG Americas Securities LLC purchased a new stake in Acumen Pharmaceuticals in the first quarter worth about $52,000. Chicago Partners Investment Group LLC increased its stake in shares of Acumen Pharmaceuticals by 34.9% during the fourth quarter. Chicago Partners Investment Group LLC now owns 18,315 shares of the company’s stock valued at $70,000 after purchasing an additional 4,736 shares in the last quarter. American Century Companies Inc. increased its position in Acumen Pharmaceuticals by 31.3% during the 2nd quarter. American Century Companies Inc. now owns 45,444 shares of the company’s stock valued at $110,000 after buying an additional 10,840 shares in the last quarter. Finally, Rhumbline Advisers purchased a new position in Acumen Pharmaceuticals during the second quarter valued at $127,000. Hedge funds and other institutional investors own 71.01% of the company’s stock.
About Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
See Also
- Five stocks we like better than Acumen Pharmaceuticals
- What is the Shanghai Stock Exchange Composite Index?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- MarketBeat Week in Review – 8/12 – 8/16
- High Dividend REITs: Are They an Ideal Way to Diversify?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.